Back to Search Start Over

Stem cell-derived exosomes and copper sulfide nanoparticles attenuate the progression of neurodegenerative disorders induced by cadmium in rats.

Authors :
Zaazaa AM
Abd El-Motelp BA
Ali NA
Youssef AM
Sayed MA
Mohamed SH
Source :
Heliyon [Heliyon] 2021 Dec 16; Vol. 8 (1), pp. e08622. Date of Electronic Publication: 2021 Dec 16 (Print Publication: 2022).
Publication Year :
2021

Abstract

The goal of the current study was to investigate the therapeutic effects of exosomes derived from mesenchymal stem cells (MSCs-Exo) and copper sulfide nanoparticles (CuSNPs) as biomaterials in order to understand the mechanisms that contribute to overcoming cadmium (Cad) induced neurological disorders in rats. Animals were divided into five groups (n = 10): group 1 was served as a negative control and receive vehicle saline (Con), group 2 Positive control groups were received Cad as cadmium chloride at a dose of 20 mg/kg/day for six weeks (Cad group), group 3 was received Cad plus MSCs-Exo as a single dose of 100 μLi. v. (Cad + MSCs-Exo), group 4 was received Cad plus CuSNPs at a dose of 6.5 mg/kg orally (Cad + CuSNPs), group 5 was received Cad + MSCs-Exo + CuSNPs for six weeks. However, the activities of each acetylcholine (Ach), acetylcholinesterase (AchE), total antioxidant status (TAC) were measured. Also, the levels of ROS, nuclear factor kappa B (NF-κB), tumor necrosis factor-α (TNF-α), Brain brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) were evaluated. Beneficial effects on the behavior of animals were observed after treatment with MSCs-Exo and CuSNPs. Furthermore, the administration of MSCs-Exo and CuSNPs have been improve the TAC, BDNF and NGF via ameliorating the oxidative stress and inflammatory markers. Moreover, Histopathological studies had shown that great development in the brain of Cad rats treated with MSCs-Exo and CuSNPs. In conclusion, this study offers an overview of innovative stem cell therapy techniques and how to integrate them with nanotechnology to boost therapeutic performance.<br />Competing Interests: The authors declare no conflict of interest.<br /> (© 2021 The Authors.)

Details

Language :
English
ISSN :
2405-8440
Volume :
8
Issue :
1
Database :
MEDLINE
Journal :
Heliyon
Publication Type :
Academic Journal
Accession number :
35028441
Full Text :
https://doi.org/10.1016/j.heliyon.2021.e08622